Amylyx Pharmaceuticals Inc (AMLX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2021 | 12-2020 | |
| Cash Flows From Operating Activities | ||
| Net Income | -14,523 | -42,280 |
| Depreciation Amortization | 10 | 1 |
| Accounts payable and accrued liabilities | 177 | N/A |
| Other Working Capital | -634 | 2,599 |
| Other Operating Activity | 2,327 | 2,983 |
| Operating Cash Flow | $-12,643 | $-36,697 |
| Cash Flows From Investing Activities | ||
| PPE Investments | -14 | -151 |
| Investing Cash Flow | $-14 | $-151 |
| Cash Flows From Financing Activities | ||
| Debt Issued | 26,159 | N/A |
| Debt Repayment | -263 | N/A |
| Common Stock Issued | 31 | N/A |
| Other Financing Activity | 0 | 46,823 |
| Financing Cash Flow | $25,927 | $46,823 |
| Beginning Cash Position | 13,066 | 3,091 |
| End Cash Position | 26,336 | 13,066 |
| Net Cash Flow | $13,270 | $9,975 |
| Free Cash Flow | ||
| Operating Cash Flow | -12,643 | -36,697 |
| Capital Expenditure | -14 | N/A |
| Free Cash Flow | -12,657 | -36,697 |